GOSS
GOSS
NASDAQ · Biotechnology

Gossamer Bio Inc

$0.38
+0.01 (+1.61%)
As of Mar 24, 3:01 PM ET ·
Financial Highlights (FY 2026)
Revenue
130.28M
Net Income
-64,215,723
Gross Margin
Profit Margin
-49.3%
Rev Growth
D/E Ratio
6.70
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 54.6% 54.6% 54.6%
Operating Margin -52.2% 16.7% 17.5% 15.5%
Profit Margin -49.3% 13.7% 12.9% 13.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 130.28M 95.94M 101.30M 82.00M
Gross Profit 52.40M 55.33M 44.79M
Operating Income -68,059,107 16.00M 17.71M 12.71M
Net Income -64,215,723 13.15M 13.02M 10.81M
Gross Margin 54.6% 54.6% 54.6%
Operating Margin -52.2% 16.7% 17.5% 15.5%
Profit Margin -49.3% 13.7% 12.9% 13.2%
Rev Growth +8.6% -0.1% -2.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 52.54M 246.05M 242.42M 231.61M
Total Equity 7.85M 241.28M 245.05M 267.08M
D/E Ratio 6.70 1.02 0.99 0.87
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -51,187,563 20.01M 19.52M 14.99M
Free Cash Flow 11.25M 11.45M 12.65M